X4 Pharmaceuticals Inc (NAS:XFOR)
$ 0.371 -0.022 (-5.6%) Market Cap: 63.27 Mil Enterprise Value: 10.25 Mil PE Ratio: 0 PB Ratio: 1.06 GF Score: 30/100

X4 Pharmaceuticals Inc at Stifel Healthcare Conference Transcript

Nov 15, 2022 / 08:00PM GMT
Release Date Price: $1.9 (-0.52%)
Stephen Willey
Stifel Nicolaus - Analyst

I'm Stephen Willey, one of the senior biotech analysts here at Stifel. Glad to have with us for the next session Paula Ragan who is the Chief Executive Officer of X4 and the Chief Financial Officer, Adam Mostafa, is also in attendance as well. We're just going to have kind of an informal chat. If anyone has a question at any point, feel free to raise your hand. We'll try to get you acknowledged and get your questions asked and answered. Paula, not sure if you want to make any kind of opening comments before we get into Q&A.

Paula Ragan
X4 Pharmaceuticals, Inc. - CEO & President

Sure. We're -- so thank you for hosting. Thanks to the Stifel team for this conference. It's nice to be in person with everyone. And I think we're really excited about where the company is at. We're on the cusp of Phase 3 data. We just had a great readout in September and a broader indication. And certainly coming off the crazy biotech markets of 2022, we're in a really nice position for a successful 2023 and beyond. So great to be here

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot